First-in-human trial exploring safety, antitumor activity, and pharmacokinetics of Sym013, a recombinant pan-HER antibody mixture, in advanced epithelial malignancies
Sign Up to like & getrecommendations! Published in 2022 at "Investigational New Drugs"
DOI: 10.1007/s10637-022-01217-7
Abstract: Purpose. Sym013 contains six humanized monoclonal antibodies that bind to non-overlapping epitopes on three human epidermal growth factor receptors (HER1-3). Preclinical studies suggested Sym013 strongly suppresses growth of multiple epithelial tumors. This is a first-in-human… read more here.
Keywords: exploring safety; advanced epithelial; trial; epithelial malignancies ... See more keywords
EBV infection in epithelial malignancies induces resistance to antitumor natural killer cells via F3-mediated platelet aggregation.
Sign Up to like & getrecommendations! Published in 2022 at "Cancer research"
DOI: 10.1158/0008-5472.can-21-2292
Abstract: Nasopharyngeal carcinoma (NPC) and Epstein-Barr virus (EBV)-associated gastric carcinoma (EBVaGC) are two major EBV-associated epithelial malignancies, both of which are characterized by the infiltration of a large number of lymphocytes, including natural killer (NK) cells.… read more here.
Keywords: epithelial malignancies; ebv associated; mediated platelet; platelet aggregation ... See more keywords
Editorial: Epigenetic drugs and therapeutic resistance for epithelial malignancies
Sign Up to like & getrecommendations! Published in 2023 at "Frontiers in Pharmacology"
DOI: 10.3389/fphar.2023.1208518
Abstract: Epigenetic modifications are widely recognized for their crucial role in the development and progression of cancer, particularly in epithelial malignancies. These changes involve modifications to DNA molecules and their associated proteins that can influence gene… read more here.
Keywords: cancer; epithelial malignancies; development; resistance ... See more keywords